Advertisement

Acute Kidney Injury: Transition to Chronic Kidney Disease

  • Daisuke Katagiri
  • Eisei NoiriEmail author
  • Ryo Matsuura
  • Raymond C. Harris
Chapter

Abstract

Acute kidney injury (AKI) is a syndrome characterized by rapid or sudden decrease in kidney function, often accompanied with oliguria, which happens within a few days. Restoration from AKI is not always simple. If it sustained or repeated, patient will potentially develop chronic kidney disease (CKD) in some days. The illness trajectory from AKI to CKD is more found in persistent type of AKI, transit to acute kidney diseases (AKD), in which kidney injury is ongoing. Here we describe a representative case of AKI after cisplatin treatment for chemotherapy for squamous cell carcinoma (SCC) which leads to CKD. This review discussed referring to the recent interpretation in this area clarifying the clinical evaluation point. Our experimental rodent model which develops CKD after cisplatin-induced AKI is also shown. The future strategy to close up the potential worsening cohort in AKI is proposed in combination with diagnosis and therapeutic intervention.

Keywords

AKI Acute kidney diseases (AKD) cisplatin-induced AKI L-FABP, liver fatty acid binding protein VAP-1, vascular adhesion protein-1 

References

  1. Bellomo R, Ronco C, Kellum JA et al (2004) Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the second international consensus conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8:R204–R212CrossRefGoogle Scholar
  2. Bonventre JV (2014) Primary proximal tubule injury leads to epithelial cell cycle arrest, fibrosis, vascular rarefaction, and glomerulosclerosis. Kidney Int Suppl 4:39–44CrossRefGoogle Scholar
  3. Borges FT, Melo SA, Ozdemir BC et al (2013) TGF-beta1-containing exosomes from injured epithelial cells activate fibroblasts to initiate tissue regenerative responses and fibrosis. J Am Soc Nephrol 24:385–392CrossRefGoogle Scholar
  4. Cerda J, Lameire N, Eggers P et al (2008) Epidemiology of acute kidney injury. Clin J Am Soc Nephrol 3:881–886CrossRefGoogle Scholar
  5. Chawla LS, Bellomo R, Bihorac A et al (2017) Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol 13:241–257CrossRefGoogle Scholar
  6. Grams ME, Sang Y, Coresh J et al (2016) Candidate surrogate end points for ESRD after AKI. J Am Soc Nephrol 27:2851–2859PubMedPubMedCentralGoogle Scholar
  7. Humphreys BD, Cantaluppi V, Portilla D et al (2016) Targeting endogenous repair pathways after AKI. J Am Soc Nephrol 27:990–998CrossRefGoogle Scholar
  8. Katagiri D, Hamasaki Y, Doi K et al (2013) Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection. J Am Soc Nephrol 24:2034–2043CrossRefGoogle Scholar
  9. Katagiri D, Hamasaki Y, Doi K et al (2015) Interstitial renal fibrosis due to multiple cisplatin treatments is ameliorated by semicarbazide-sensitive amine oxidase inhibition. Kidney Int 89:374–385CrossRefGoogle Scholar
  10. KDIGO (2012) Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2:1–124CrossRefGoogle Scholar
  11. KDIGO (2013) Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1–116CrossRefGoogle Scholar
  12. Kellum JA, Lameire N (2013) Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 17:204CrossRefGoogle Scholar
  13. Lam AQ, Humphreys BD (2012) Onco-nephrology: AKI in the cancer patient. Clin J Am Soc Nephrol 7:1692–1700CrossRefGoogle Scholar
  14. Mack M, Yanagita M (2015) Origin of myofibroblasts and cellular events triggering fibrosis. Kidney Int 87:297–307CrossRefGoogle Scholar
  15. Mehta RL, Kellum JA, Shah SV et al (2007) Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 11:R31CrossRefGoogle Scholar
  16. Mehta RL, Cerda J, Burdmann EA et al (2015) International Society of Nephrology’s 0by25 initiative for acute kidney injury (zero preventable deaths by 2025): a human rights case for nephrology. Lancet 385:2616–2643CrossRefGoogle Scholar
  17. Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73:994–1007CrossRefGoogle Scholar
  18. Schetz M, Dasta J, Goldstein S et al (2005) Drug-induced acute kidney injury. Curr Opin Crit Care 11:555–565CrossRefGoogle Scholar
  19. Wei Q, Dong G, Franklin J et al (2007) The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int 72:53–62CrossRefGoogle Scholar
  20. Yang L, Besschetnova TY, Brooks CR et al (2010) Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 16:535–543, 531p following 143CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  • Daisuke Katagiri
    • 1
    • 2
    • 3
  • Eisei Noiri
    • 1
    Email author
  • Ryo Matsuura
    • 1
  • Raymond C. Harris
    • 2
  1. 1.Department of Nephrology and EndocrinologyUniversity Hospital, The University of TokyoTokyoJapan
  2. 2.Department of Hemodialysis and Apheresis, 107 LaboratoryUniversity Hospital, The University of TokyoTokyoJapan
  3. 3.Division of NephrologyVanderbilt University Medical CenterNashvilleUSA

Personalised recommendations